European Society for Clinical Investigation

ClinOne Raises Additional Funding from Boulder Ventures and Highpoint Ventures in its Series A Extension; Names Top Life Science Leaders to its Board of Directors

Retrieved on: 
Mittwoch, November 1, 2023
Associate, Woman, Jeanmarie Simpson, Eli Lilly and Company, Biomedical data science, SMO, Health care, Health, Therapy, Eli Lilly, RN, Entrepreneurship, Contract research organization, Clinical research associate, COVID-19 vaccine, Quality of life, COVID-19, Retirement, Site management organization, European Society for Clinical Investigation, Statistics, Public, Series, Patient, Nursing, Management, Pharmaceutical industry, Lilly

BOSTON and BOULDER, Colo., Nov. 1, 2023 /PRNewswire-PRWeb/ -- Jason Grimes, Co-Founder and Managing Director at Highpoint Ventures stated, "We are excited to partner with ClinOne and are impressed with the management team. We support ClinOne's mission to transform the experiences of clinical sites and how they operate to more effectively to serve participants."

Key Points: 
  • The initial Series A funding round was announced in April and was led by venture capital firm Boulder Ventures with participation by existing investors.
  • In this round, Boulder Ventures and Highpoint Ventures joined to extend the funding.
  • ClinOne also announced the appointment of two accomplished Life Sciences leaders to its Board: Katherine Vandebelt and JeanMarie Markham, RN.
  • Katherine joins the ClinOne Board from her work as the Global Vice President of Clinical Innovation at Oracle Life Sciences.

Onconova Expands Leadership Team with Two Key Appointments

Retrieved on: 
Dienstag, Oktober 24, 2023
Drug development, Research, Bone marrow, Ovarian cancer, Nottingham Trent University, Medicine, Internal medicine, Bachelor, Biomedical sciences, George Washington School, Pediatric Hematology and Oncology, Medical Affairs Bureau, Pharmacy, European Society for Clinical Investigation, Pharmaceutical medicine, University of Zimbabwe, Postgraduate diploma, Epidermolysis bullosa, University, NDA, Cancer, Therapy, Patient, Myelodysplastic syndrome, Merrimack Pharmaceuticals, GSK plc, Medication, CMO, Nottingham, Johns Hopkins School of Medicine, King's College London, University of Surrey, IND, Consultant, Outline of health sciences, Patent, Rare, Inflammation, R, EB, Johnson & Johnson, Pharmaceutical industry, Nursing, Biotechnology, Science, Hematology, Honours degree

NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer (CMO), and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development (R&D).

Key Points: 
  • Both are accomplished experts in their fields and bring significant and wide expertise in drug development.
  • I look forward to working with my colleagues at Onconova and our clinical collaborators to contribute to our mission of bringing narazaciclib and rigosertib to patients with cancer.
  • He has also held various leadership roles as Vice President of Clinical Investigations at Merrimack Pharmaceuticals and the Centocor Ortho Biotech Services, LLC division of Johnson & Johnson.
  • Prior to that, she held various leadership roles as Medical Director or Associate Medical Director, as well as roles in Investigator Research and Medical Affairs at Celgene International.

Mary Kay Inc. & European Society for Dermatological Research Partner to Award Educational Research Grants Advancing Skin Health/Skin Disease

Retrieved on: 
Mittwoch, Mai 17, 2023
Cosmetics, Men, Retail, Health, Consumer, Lifestyle, Oncology, Research, Infectious Diseases, General Health, Genetics, Fitness & Nutrition, Science, Women, Human, Society, Partnership, Skin care, ETH, Human Cell Atlas, Skin, Dermatology, Skin cancer, Cancer, ESDR, Multimedia, Regenerative medicine, Assistant professor, Vivo, Tissue Engineering and Regenerative Medicine International Society, Mary Kay, Gene therapy, ISCB Senior Scientist Award, Biology, European Society for Clinical Investigation, Carcinoma, BCC, Tumor microenvironment, Conference, Pharmaceutical industry

Mary Kay Inc. , a global leader in skin care innovation, in partnership with the European Society for Dermatological Research , recently announced its inaugural Mary Kay Skin Health/Skin Disease Research Grant awardees at a special virtual event prior to the First International Societies for Investigative Dermatology conference in May.

Key Points: 
  • Mary Kay Inc. , a global leader in skin care innovation, in partnership with the European Society for Dermatological Research , recently announced its inaugural Mary Kay Skin Health/Skin Disease Research Grant awardees at a special virtual event prior to the First International Societies for Investigative Dermatology conference in May.
  • View the full release here: https://www.businesswire.com/news/home/20230517005040/en/
    Mary Kay partnered with European Society for Dermatological Research (ESDR) to award inaugural Mary Kay-ESDR Skin Health/Skin Disease Research Grants.
  • Congratulations to our 2022 recipients, Dr. Clarisse Ganier and Dr. Michael Cangkrama, who will each receive $20,000 grants to further their contributions in skin disease research.
  • (Photo: Mary Kay Inc.)
    “Mary Kay is dedicated to advancing skin and nutritional health research globally, and we know this cannot be done alone.

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

Retrieved on: 
Mittwoch, Mai 18, 2022
Cancer, Hapten, Disease, HCL, Ovarian cancer, European Society of Gynaecological Oncology, Center, EMA, Standard of care, Immune system, FRA, OTCQB, University Hospital Center Dr Dragiša Mišović, GMP, Woman, Clinical trial, COVID-19, CSE, III, Hospital, Neoplasm, Company, Survival, Peritoneum, Doctor of Philosophy, Vaccine, Trial of the century, FDA, Obstetrics, Biotechnology, Good, Toxicity, CTA, European Medicines Agency, Heart, Hospices Civils de Lyon, Protein, Severe acute respiratory syndrome coronavirus 2, Cryopreservation, Patient, International Journal of Gynecology & Obstetrics, National Cancer Institute, IND, European Society for Clinical Investigation, Prognosis, Head, ProCare, Usha Menon, Pharmaceutical industry, Medical imaging, Lyon Metropolis, MD, EU, BC

HCL is a public hospital and France's second University Hospital Center, and a premier site for clinical studies in the EU.

Key Points: 
  • HCL is a public hospital and France's second University Hospital Center, and a premier site for clinical studies in the EU.
  • Benot You, MD, PhD, of HCL who are planned Clinical Investigators for the Phase I study of BVX-0918.
  • BioVaxys is preparing to file a Clinical Trial Application ("CTA") with the European Medicines Agency ("EMA") later in 2022.
  • Access to surgically removed ovarian cancer tumor cells is a critical step enabling BioVaxys to validate the manufacturing process for BVX-0918.

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

Retrieved on: 
Mittwoch, Mai 18, 2022
Cancer, Hapten, Disease, HCL, Ovarian cancer, European Society of Gynaecological Oncology, Center, EMA, Standard of care, Immune system, FRA, OTCQB, University Hospital Center Dr Dragiša Mišović, GMP, Woman, Clinical trial, COVID-19, CSE, III, Hospital, Neoplasm, Company, Survival, Peritoneum, Doctor of Philosophy, Vaccine, Trial of the century, FDA, Obstetrics, Biotechnology, Good, Toxicity, CTA, European Medicines Agency, Heart, Hospices Civils de Lyon, Protein, Severe acute respiratory syndrome coronavirus 2, Cryopreservation, Patient, International Journal of Gynecology & Obstetrics, National Cancer Institute, IND, European Society for Clinical Investigation, Prognosis, Head, ProCare, Usha Menon, Pharmaceutical industry, Medical imaging, Lyon Metropolis, MD, EU, BC

HCL is a public hospital and France's second University Hospital Center, and a premier site for clinical studies in the EU.

Key Points: 
  • HCL is a public hospital and France's second University Hospital Center, and a premier site for clinical studies in the EU.
  • Benot You, MD, PhD, of HCL who are planned Clinical Investigators for the Phase I study of BVX-0918.
  • BioVaxys is preparing to file a Clinical Trial Application ("CTA") with the European Medicines Agency ("EMA") later in 2022.
  • Access to surgically removed ovarian cancer tumor cells is a critical step enabling BioVaxys to validate the manufacturing process for BVX-0918.